7. Sepsis Bundles & Source Control (2026 SSC Update)

Quick Recap

Tier 1 expansion protocol — Infectious Diseases System. Companion to the existing Septic Shock protocol (1/6), which covers hemodynamic management in depth; this protocol focuses specifically on the performance-improvement/bundle infrastructure and source control decision-making that sit upstream of and alongside hemodynamic resuscitation. Cross-reference Vasopressor & Inotrope Selection & Titration (Cardiovascular System) for vasopressor specifics.

⚠️ IMPORTANT — GUIDELINE UPDATE FLAG: This protocol is built on the 2026 Surviving Sepsis Campaign guidelines (Prescott, Antonelli, Alhazzani et al., jointly published in Intensive Care Medicine and Critical Care Medicine, March 2026), which meaningfully update the 2021 SSC guidelines with 129 total statements (46 entirely new). This publication postdates typical knowledge cutoffs and may not be reflected in the existing Septic Shock protocol (1/6) in this library, which was likely built on 2021-era guidance. Recommend reviewing and updating the existing Septic Shock protocol against this newer guideline — key changes are flagged inline below where they diverge from 2021.

1. Definition

Sepsis performance improvement (PI) / quality improvement (QI) programs: structured, ongoing institutional processes — sepsis screening for acutely ill/high-risk patients, standard operating procedures for treatment, and continuous QI strategies — now a strongly recommended, newly formalized component of sepsis care in the 2026 SSC guideline, reflecting evidence that systems-level infrastructure, not just individual clinician knowledge, drives outcomes.

Source control: any physical intervention (drainage, debridement, device removal, definitive surgical or interventional management) required to eliminate a focus of infection that antimicrobials alone cannot resolve — abscesses, infected devices/hardware, necrotic tissue, obstructed hollow viscus with infection (e.g., cholangitis, obstructed ureter with pyonephrosis).

"Code sepsis": an institutional rapid-response activation analogous to code stroke/STEMI, intended to compress the time from recognition to first antimicrobial dose and source control evaluation — explicitly endorsed as part of the 2026 PI framework.

2. Pathophysiology

The rationale for bundled, time-sensitive care rests on the biology of unchecked infection: ongoing bacterial/toxin burden drives progressive endothelial injury, coagulation activation, and cytokine-mediated organ dysfunction that becomes progressively less reversible the longer the causative source remains unaddressed. Source control interrupts this process at its origin; antimicrobials alone cannot achieve source control when a physical focus (abscess, necrotic tissue, infected foreign material) is present, because achievable antimicrobial tissue penetration is inadequate into avascular, necrotic, or walled-off collections — this is the core biological reason source control is a distinct, non-negotiable pillar alongside antimicrobial therapy rather than a redundant add-on.

The 2026 guideline explicitly frames the overall certainty of evidence for early-intervention timing recommendations (antimicrobials, source control) as very low, since the evidence base is overwhelmingly observational with residual confounding, inconsistent "time zero" definitions, and inherent difficulty randomizing patients to delayed treatment for ethical reasons — the strength of these recommendations reflects biological plausibility and consistent directional signal across many studies, not high-certainty RCT evidence, and this distinction is worth holding onto rather than treating hour-based cutoffs as precisely established truths.

3. Immediate Stabilization (ABCDE) — Bundle-Specific Actions

Airway

Breathing

Circulation

Disability

Exposure

Decision point: source control evaluation should happen in parallel with hemodynamic resuscitation and antimicrobial administration from the first assessment, not sequentially after the patient is "stabilized" — an unaddressed source will continue to drive instability regardless of vasopressor titration.

4. Focused History

• Onset and progression timeline (establishes "time zero" for bundle metrics)
• Recent procedures, devices, hardware, catheters (potential infected foreign material requiring removal)
• Recent surgery (anastomotic leak, surgical site infection as an occult source)
• Immunosuppression status (alters both source control urgency and antimicrobial breadth — cross-reference Febrile Neutropenia, Opportunistic Infections protocols)
• Travel/exposure history (informs pathogen-specific and multidrug-resistant organism risk)
• Recent antimicrobial exposure (resistance risk, informs empiric selection)
• Prehospital course — 2026 guideline suggests prehospital antibiotic administration during transport for septic shock patients when delays to hospital treatment are expected, where feasible

5. Comprehensive System-wise Examination

Systematic examination specifically oriented toward identifying a source amenable to physical intervention, in addition to standard sepsis assessment:

• Skin/soft tissue: cellulitis, abscess, necrotizing infection signs (cross-reference Necrotizing Fasciitis protocol)
• Abdomen: peritonitis, localized tenderness suggesting intra-abdominal collection
• Genitourinary: flank tenderness (obstructing pyonephrosis), indwelling catheter assessment
• Vascular access/hardware: any indwelling line, prosthetic material, or device as a potential infected focus requiring removal
• Surgical wounds: dehiscence, discharge, evidence of deep space infection

POCUS integration: 2026 guideline includes a new conditional recommendation for POCUS to guide resuscitation — in addition to its established role in identifying an occult source (abscess, effusion, obstructive uropathy) that may require intervention.

6. Syndrome Identification

Cross-reference the full Septic Shock protocol (1/6) for hemodynamic syndrome classification. The specific task of this protocol is: has a source requiring physical intervention been identified, and if so, has a plan and timeline for that intervention been established? This is a distinct checkpoint from hemodynamic stabilization and should not be deferred until the patient is hemodynamically settled.

7. Differential Diagnosis

Cross-reference Septic Shock protocol (1/6) for the full differential of sepsis mimics. This protocol's specific differential concern is distinguishing sources that require physical intervention from those that resolve with antimicrobials alone:

Requires source control:

• Abscess (any location)
• Infected/obstructed device or hardware
• Necrotizing soft tissue infection
• Obstructed, infected hollow viscus (cholangitis with obstruction, pyonephrosis, empyema)
• Anastomotic leak/intra-abdominal collection

Generally antimicrobial-responsive without physical intervention:

• Uncomplicated pneumonia
• Uncomplicated pyelonephritis (without obstruction)
• Uncomplicated bacteremia without an identified drainable focus

8. Severity Assessment

Screening tools: 2026 guideline now favors SIRS criteria and Modified Early Warning Score (MEWS) over qSOFA for sepsis screening, reflecting qSOFA's lower sensitivity for early identification — this is a meaningful shift from recent practice patterns that had increasingly emphasized qSOFA.

SOFA score: remains the standard for defining sepsis-associated organ dysfunction (Sepsis-3 framework), cross-reference Septic Shock protocol.

Performance metrics: time-to-antibiotics, time-to-source-control-intervention, and bundle-element completion are themselves severity-adjacent process metrics tracked at the institutional level under the PI/QI framework (Section 16).

9. Investigations

Immediate bedside: blood cultures (×2 sets, before antimicrobials where feasible without meaningful delay), lactate, point-of-care imaging (POCUS) to screen for a drainable source

Routine labs: standard sepsis workup per Septic Shock protocol

Microbiology: cultures from all suspected sources (urine, wound, respiratory, line tips if removed) in addition to blood cultures; rapid diagnostic testing use should be guided by local epidemiology and antimicrobial stewardship principles per 2026 guidance, rather than applied indiscriminately

Imaging: source-directed imaging (CT abdomen/pelvis, ultrasound, etc.) should be expedited specifically when a drainable/resectable source is suspected — do not let imaging turnaround delay empiric antimicrobial administration, but do not let hemodynamic-focused care delay the imaging needed to identify a source requiring intervention

10. Point-of-Care Ultrasound

Newly and explicitly endorsed (conditional recommendation) in the 2026 SSC guideline to guide resuscitation, in addition to its established diagnostic role here in identifying occult sources (intra-abdominal collections, obstructive uropathy with hydronephrosis, pleural/pericardial effusions, line-associated thrombophlebitis) that may require source control intervention. Integrate POCUS findings into the source control decision at first assessment, not as a delayed confirmatory step.

11. Evidence-Based Management

Performance Improvement Infrastructure (2026 — Newly Formalized, Strongly Recommended)

• Strong recommendation: hospitals/health systems should use a performance improvement program for sepsis — sepsis screening for acutely ill/high-risk patients, standard operating procedures for treatment, and ongoing QI strategies
• Supporting evidence: the SCREEN trial (stepped-wedge cluster RCT, 60,055 patients) found that implementation of an electronic alert system plus staff education and feedback was associated with lower 90-day in-hospital mortality in patients with and without sepsis (adjusted RR 0.85, 95% CI 0.77–0.93) — a systems-level intervention with a broader-than-expected benefit signal
• A dedicated hour-1 bundle implementation RCT (n=872, ED setting) found the standard operating procedure reduced time to antibiotics by 73 minutes (95% CI, 53–93 min sooner), with an uncertain but directionally favorable mortality signal (aRR 0.81, 95% CI 0.48–1.39) — underpowered for mortality but consistent with benefit

Screening

• Favor SIRS criteria and MEWS over qSOFA for sepsis screening (2026 update — reverses recent qSOFA-forward practice trends)
• Standardized screening tools suggested even in the prehospital setting (ambulance/flight transport)

Antimicrobial Timing

• Possible septic shock or high likelihood of sepsis: administer antimicrobials immediately, ideally within 1 hour of recognition (carried forward from 2021, reinforced)
• Probable or definite sepsis without shock: 2026 guideline now recommends (upgraded from "suggests" in 2021) immediate antimicrobial therapy, ideally within 1 hour — certainty of evidence remains very low, but the recommendation strength increased
• Possible sepsis without shock: a time-limited course of rapid investigation is suggested; if concern for infection persists and diagnostic capability to exclude a noninfectious cause is not readily available, antimicrobials should be given without further delay
• Prehospital antibiotics: newly suggested for septic shock patients when delays to hospital treatment are expected, feasibility permitting
• Draw blood cultures before antimicrobials wherever this does not cause meaningful delay

Antimicrobial Selection and Stewardship

• Empiric coverage should be tailored to multidrug-resistant organism risk and anaerobic risk profile based on source and local epidemiology, not uniformly broad-spectrum by default
• Prolonged/continuous infusion of beta-lactams (after an initial loading dose) is now a strong recommendation over bolus/intermittent dosing (upgraded from conditional in 2021) — reflects accumulating PK/PD evidence for sustained time-above-MIC in critically ill patients
• Continuous reevaluation and de-escalation once culture data and clinical trajectory allow; discontinue empiric antimicrobials if an alternative, noninfectious cause is identified or strongly suspected
• New recommendations against: routine antipyretics for outcome improvement (symptom relief still reasonable), probiotics, and beta-blockers for treatment of sepsis/septic shock

Source Control

• Core principle (carried forward and reinforced): rapidly evaluate for infection sources requiring intervention (abscess, infected device) as part of the initial assessment
• 2026 specific timing guidance: source control should be achieved as early as possible, ideally within 6 hours of diagnosis — this is a more specific numerical target than the 2021 language ("as soon as medically and logistically practical and safe"), while the guideline is explicit that this recommendation rests on observational evidence only
• Source control planning (surgical, interventional radiology, endoscopic, or device removal as appropriate to the source) should begin the moment a drainable/resectable/removable focus is identified, run in parallel with ongoing hemodynamic resuscitation, and not be delayed pending complete hemodynamic stabilization when the source itself is the primary driver of instability
• Infected device/hardware: remove or exchange promptly once identified as the likely source, balanced against the practical complexity of removal in specific cases (e.g., complex prosthetic material) — this balance requires the relevant proceduralist/surgical input early (Section 14)

Fluid Management — Beyond Initial Resuscitation

• New 2026 recommendation: consider active fluid removal (de-resuscitation) after completion of the initial resuscitation phase to prevent fluid overload — reflects growing recognition that the risk profile shifts from under-resuscitation in the first hours to fluid-overload-related harm in the subsequent 24–72 hours; this is a genuine shift in framing from a purely "more fluid is protective" early mindset toward a two-phase resuscitation-then-de-resuscitation model

ICU Admission Timing

• Suggest ICU admission within 6 hours for adults with sepsis/septic shock requiring ICU-level care (carried from 2021); delayed ED-to-ICU transfer is associated with reduced bundle compliance and increased mortality, ventilator days, and length of stay in observational data

12. Organ Support

Cross-reference full organ support detail in the Septic Shock protocol (1/6) and Vasopressor & Inotrope Selection & Titration protocol (Cardiovascular System). This protocol's specific addition: respiratory support device selection for sepsis-associated respiratory failure now favors HFNC as initial device (2026), with individualized O2 targets and awake proning consideration, and higher tidal volumes (6–8 mL/kg) acceptable specifically in the absence of established lung injury.

13. Disease-Specific Therapy

• Beta-lactam antibiotics: administer as prolonged/continuous infusion after an initial loading dose (strong recommendation, 2026) rather than standard intermittent bolus dosing
• Empiric regimen selection: per local antibiogram, suspected source, and multidrug-resistant organism risk factors — cross-reference institutional antimicrobial stewardship guidance
• Avoid: routine antipyretics for outcome improvement, probiotics, beta-blockers as sepsis-specific therapies (2026 recommendations against)

14. Consultation Matrix

15. Monitoring Framework

• Process metrics (institutional PI/QI level): time-to-antibiotics, time-to-source-control-intervention, blood culture-before-antibiotics compliance, bundle element completion rates — tracked and fed back per the 2026-endorsed QI framework
• Clinical: standard sepsis monitoring per Septic Shock protocol
• Fluid balance: track cumulative balance explicitly to identify the transition point from resuscitation to de-resuscitation phase (Section 11)
• Escalation triggers: unidentified or unaddressed source with ongoing instability → escalate source-control evaluation urgency; persistent fever/instability despite adequate antimicrobials and apparent source control → reassess for an alternative or additional undrained focus

16. ICU Bundle Checklist

17. Complications

Early:

• Ongoing hemodynamic instability from an unaddressed source despite adequate antimicrobials
• Antimicrobial-related adverse effects (nephrotoxicity, C. difficile) from unnecessarily broad or prolonged empiric therapy
• Procedural complications from source control intervention (bleeding, injury to adjacent structures)

Late:

• Post-sepsis cognitive, physical, and psychological morbidity (Section 19) — a growing focus of the 2026 guideline's post-hospital section
• Antimicrobial resistance from stewardship lapses
• Recurrent infection from incomplete source control

Prevention: systematic PI/QI infrastructure, parallel (not sequential) pursuit of source control alongside hemodynamic resuscitation, antimicrobial stewardship discipline

Rescue: reassess for an undrained or missed source in any patient failing to improve as expected despite apparently adequate antimicrobial therapy and hemodynamic support

18. Escalation & De-escalation

Escalation: unidentified source with ongoing instability → expedite source-directed imaging and proceduralist involvement; persistent instability despite apparent source control → reassess for an additional or missed focus.

De-escalation: narrow antimicrobial spectrum per culture data and clinical response; discontinue if a noninfectious cause is identified; transition from resuscitation to active de-resuscitation phase once initial hemodynamic targets are met (2026 addition).

19. ICU Discharge Criteria

Cross-reference Septic Shock protocol (1/6) for standard physiological discharge criteria. Additional consideration per 2026 guideline's expanded post-hospital focus: counsel patients/families regarding expected post-sepsis morbidity (physical, cognitive, psychological) and ensure appropriate follow-up planning is documented at discharge — this reflects a genuine expansion of guideline scope beyond acute management into survivorship.

20. Documentation & Medicolegal Checklist

• Time of sepsis recognition ("time zero") documented explicitly, as this anchors all bundle metrics
• Blood culture timing relative to antimicrobial administration documented
• Source control evaluation documented at first assessment, including rationale if no intervenable source identified
• Source control intervention timing tracked against the 6-hour target, with rationale documented for any delay
• Antimicrobial selection rationale (empiric coverage, de-escalation decisions) documented
• Institutional PI/QI metrics captured per local sepsis program requirements
• Post-sepsis morbidity counseling documented at discharge

21. Key Guidelines

• Surviving Sepsis Campaign 2026 (Prescott, Antonelli, Alhazzani et al., jointly published Intensive Care Med and Crit Care Med, March 2026): 129 statements, 46 entirely new, updating the 2021 guideline. Developed by a 69-person international panel across 23 countries. This is the current authoritative guideline and should inform revision of the existing Septic Shock protocol in this library.
• Surviving Sepsis Campaign 2021 (Evans et al.): prior version, largely superseded by the above for the specific elements addressed in this protocol, though much hemodynamic-management content carries forward unchanged (cross-reference Vasopressor & Inotrope Selection & Titration protocol, which already incorporates current evidence).

22. Landmark Trials

23. Controversies

• Certainty of evidence for hour-based timing targets: the 2026 guideline itself rates certainty for early-antimicrobial and source-control timing recommendations as very low — these targets (1 hour for antibiotics, 6 hours for source control) represent the best available synthesis of observational data and biological plausibility, not precisely RCT-validated cutoffs. Clinicians should treat them as strong operational defaults rather than rigid thresholds where an hour's difference is itself the determinant of outcome.
• qSOFA reversal: the shift back toward favoring SIRS/MEWS over qSOFA reverses a trend that had gained traction since Sepsis-3 (2016) emphasized qSOFA's simplicity; this reflects accumulated evidence of qSOFA's limited sensitivity for early screening, and institutions using qSOFA-based screening protocols should review this change specifically.
• Antipyretic, probiotic, and beta-blocker recommendations against: these represent areas where accumulated trial evidence has failed to show benefit despite earlier physiological rationale or smaller positive studies — worth explicit note for clinicians who may still be following older or local practice patterns favoring these interventions.
• Fluid de-resuscitation timing: the new recommendation to consider active fluid removal after initial resuscitation is a meaningful practice shift, but the guideline does not specify a precise trigger point for when "initial resuscitation" is considered complete — this remains an area requiring clinical judgment and will likely be refined in future updates.
• Existing library content gap: the Septic Shock protocol (1/6) in this library predates the 2026 guideline's publication (or at minimum has not been confirmed to incorporate it) and should be reviewed against the changes flagged throughout this protocol.

24. References

1. Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026. Intensive Care Med. 2026 Mar 23. doi:10.1007/s00134-026-08361-1.
2. Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. 2026;54(4):725-812. doi:10.1097/CCM.0000000000007075.
3. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Intensive Care Med. 2021;47:1181-1247.
4. [SCREEN trial — stepped-wedge cluster RCT of electronic alert/education/feedback intervention, cited within 2026 SSC guideline]
5. The Washington Manual of Critical Care, 4th ed. 2025 — sepsis chapters (note: predates 2026 SSC update).
6. ICU Protocols: A Step-wise Approach, 2nd ed. — sepsis syndrome chapter (note: predates 2026 SSC update).